What is Genezen?
Genezen operates as a technical and quality-focused Contract Development and Manufacturing Organization (CDMO) with a specialization in viral vector production, a critical component for developers of cell and gene therapies. The company offers a comprehensive suite of services, encompassing the manufacturing of Adeno-Associated Virus (AAV), lentiviral, and retroviral vectors, alongside plasmid design and support for cell therapy initiatives. Leveraging state-of-the-art facilities located in Indiana and Massachusetts, Genezen is committed to advancing novel therapies from their initial preclinical stages through to Good Manufacturing Practice (GMP) compliant supply. Their approach emphasizes collaborative project management, ensuring that clients receive tailored support to bring their viral vector-based therapeutic innovations to patients.
How much funding has Genezen raised?
Genezen has raised a total of $18.5M across 1 funding round:
Private Equity
$18.5M
Private Equity (2023): $18.5M with participation from Ampersand Capital Partners
Key Investors in Genezen
Ampersand Capital Partners
Ampersand Capital Partners is a prominent private equity firm known for its investments in the healthcare and technology sectors. Their involvement suggests a strategic focus on companies poised for significant growth within the life sciences industry, particularly those in specialized manufacturing or service provision.
What's next for Genezen?
The substantial enterprise-level funding secured by Genezen signals a strategic inflection point, likely enabling the company to scale its manufacturing capacity, enhance its technological infrastructure, and potentially expand its service offerings. This capital infusion is expected to fortify Genezen's position as a key partner for biopharmaceutical companies navigating the complex landscape of cell and gene therapy development. The focus on GMP-compliant production suggests an intent to support later-stage clinical trials and commercialization efforts, thereby accelerating the delivery of life-changing treatments to patients. Future strategic moves may involve further technological advancements in viral vector production or expansion into new therapeutic modalities.
See full Genezen company page
